Ernexa Therapeutics (NASDAQ:ERNA) Releases Quarterly Earnings Results, Misses Expectations By $0.10 EPS

Ernexa Therapeutics (NASDAQ:ERNA) announced its quarterly earnings results on Thursday. The company reported ($3.40) earnings per share (EPS) for the quarter, missing the consensus estimate of ($3.30) by ($0.10), FiscalAI reports.

Ernexa Therapeutics Price Performance

Shares of ERNA traded up $0.26 during mid-day trading on Thursday, hitting $4.36. 36,336 shares of the company’s stock were exchanged, compared to its average volume of 1,388,542. Ernexa Therapeutics has a 52 week low of $3.18 and a 52 week high of $71.50. The company has a market cap of $5.08 million, a PE ratio of -0.17 and a beta of 2.57. The company has a 50-day simple moving average of $6.00 and a 200 day simple moving average of $8.88.

Analyst Upgrades and Downgrades

ERNA has been the topic of several research reports. Brookline Capital Markets started coverage on Ernexa Therapeutics in a research note on Thursday, May 7th. They set a “buy” rating and a $30.00 price target on the stock. Zacks Research raised shares of Ernexa Therapeutics to a “hold” rating in a report on Monday, May 11th. Wall Street Zen raised Ernexa Therapeutics from a “sell” rating to a “hold” rating in a report on Saturday, June 27th. Finally, Weiss Ratings reissued a “sell (e+)” rating on shares of Ernexa Therapeutics in a research note on Friday, July 17th. One analyst has rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the company currently has an average rating of “Hold” and a consensus target price of $30.00.

Institutional Investors Weigh In On Ernexa Therapeutics

An institutional investor recently bought a new stake in Ernexa Therapeutics stock. Susquehanna International Group LLP acquired a new stake in Ernexa Therapeutics Inc. (NASDAQ:ERNA) in the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The firm acquired 30,854 shares of the company’s stock, valued at approximately $34,000. Susquehanna International Group LLP owned approximately 0.39% of Ernexa Therapeutics at the end of the most recent reporting period. Hedge funds and other institutional investors own 70.55% of the company’s stock.

Ernexa Therapeutics Company Profile

Eterna Therapeutics Inc, a life science company, provides mRNA cell engineering technologies. Its technologies include mRNA cell reprogramming and gene editing; NoveSlice and UltraSlice gene-editing proteins; and the ToRNAdo mRNA delivery system. The company has a license agreement with Factor Bioscience Limited. Eterna Therapeutics Inc was founded in 2018 and is based in Cambridge, Massachusetts.